When one M&A door closes, many windows open. After Pfizer wrapped up a $14B Medivation buy Monday, investors bid up BioMarin, Incyte and more as likely…

Amgen was aiming to launch its cholesterol-fighter Repatha quickly in India. But a panel of CV and renal specialists blocked the PCSK9 drug instead.

The second-guessing has begun: Would Sanofi have had a shot at winning Medivation if it hadn’t gone hostile so quickly?

This year’s stock market hasn’t been easy for pharma. Unwelcome news has sent some drugmakers' shares tumbling--as much as 72%, in one notorious case.

Instagram has just made social media easier and safer for pharma. Instagram Stories, 24-hour disappearing video and photo narrative postings, allow comments to…

Boehringer's Pradaxa won an edge on its new-age anticoagulant rivals last year when the FDA approved a reversal agent. It'll hang onto that edge, at…

Here's an unintended consequence of high drug prices: Patients feel entitled to pharma's help in paying for them.

With her poolside reporting assignment at the Olympics in Rio behind her, Olympic swimmer and 12-time medalist Dara Torres is turning her attention to another…